AKT1 and breast carcinoma: Here, we demonstrate that combined therapeutic targeting of PI3K/AKT and the H3K4 methyltransferase MLL1 decreases H3K4me3 to reduce transformative properties of human breast cancer cell lines and tumor growth in murine models, which is further enhanced following genetic loss of KMT2D/MLL4.